Kronos Bio, Inc. (NASDAQ: KRON) was founded in 2017 and is headquartered in San Mateo, California, USA. It has 45 full-time employees. It is a clinical-stage biopharmaceutical company dedicated to discovering and developing new cancer therapeutics, aiming to use precision The strategy of drug therapy is to target dysregulated transcription to transform patients’ therapeutic effects.
Kronos Bio, Inc. (KRON):
Kronos Bio is committed to discovering and developing first-class therapies that can be adjusted and cannot be targeted with drugs in the past. Kronos Bio utilizes the power of high-throughput small molecule microarrays (SMM) to target protein degradation and cancer biology to identify effective and selective compounds that target transcription factors and other major drivers of oncogenic signals.
Kronos Bio’s proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory network (TRN) that drives their carcinogenic activity. Kronos Bio’s main drug candidate, entospletinib (Entepritinib, ENTO), is an oral selective spleen tyrosine kinase (SYK) inhibitor that has been administered in 148 patients with acute myeloid leukemia (AML) Tested. Based on the clinical results of the subgroup of patients defined by biomarkers, and in discussions with the company’s regulatory agencies in the first half of 2021, Kronos Bio plans to initiate Phase II/III registration in 2021 for newly diagnosed AML patients with NPM1 mutations Clinical trials are expected to obtain data in 2023.
Kronos Bio has developed a strong clinical and pre-clinical product line. The following table summarizes the company’s product line, including Kronos Bio’s main product candidate ENTO, discovery plan and the next expected milestone.
Kronos Bio product line
Kronos Bio, Inc. (KRON) Financing:
- On June 5, 2018, Kronos Bio received US$18 million in seed funding from Vida Ventures, Omega Funds, Bellco Capital and two individual investors, Norbert Bischofberger and John Martin.
- On July 18, 2019, Kronos Bio received the lead investment from Omega Funds and Vida Ventures , and 7 institutions including GV , Polaris Partners, Perceptive Advisors, Invus and other 7 institutions participated in the investment of 105 million US dollars.
- On August 25, 2020, in Series B financing, Kronos Bio received the lead investment from Perceptive Advisors, and 14 institutions including GV, Polaris Partners, T. Rowe Price , Fidelity Management and Research Company followed up with US$155 million in funding.
Kronos Bio, Inc. (KRON) investment:
Kronos Bio, Inc. (NASDAQ:KRON) listed on the IPO on 10/9/2020 and registered on Nasdaq. The planned issue price is $16.00-$18.00, the actual issue price is $19, 10.3 million shares are issued, and 196 million US dollars are raised. Goldman Sachs / Jefferies/ Cowen/ Piper Sandler underwriting.